Search Results

You are looking at 41 - 50 of 328 items for :

  • "ovarian cancer" x
  • Refine by Access: All x
Clear All
Full access

Ying Zhou, Chenchen Zhu, Zhen Shen, Yanhu Xie, Wei Zhang, Jing Zhu, Tianjiao Zhang, Min Li, Jiwei Qin, Shuai Yin, Rongzhu Chen, Wei Wei, Sinan Sun, Guihong Wang, Zheng Zhou, Hanhui Yao, Dabao Wu, and Björn Nashan

Objective: To evaluate the postoperative complications and their impacts on the patients who have performed with primary cytoreduction (including extra upper abdominal surgery, EUAS) of advanced epithelial ovarian cancer at stage IIIc and IV

Full access

Rebecca Arend, Brandon M. Roane, Selene Mesa-Perez, Whitney N. Goldsberry, Ashwini Katre, Michael J. Birrer, and Lisa A. Norian

response to therapy. The objective of this study was to evaluate the effects of anti-TGF-β therapy in an immunocompetent ovarian cancer mouse model. Methods: ID8-p53-/- cells were injected intraperitoneally (I.P.) into C57BL/6 mice to establish our

Full access

Jordan E. Rullo and Sandhya Pruthi

preoperatively. 2 For women undergoing risk-reducing surgeries for elevated breast or ovarian cancer risk or hereditary predisposition, the impact on sexual health is one of the most influential factors when deciding to undergo these surgeries. 3 Among BRCA

Full access

Rongjia Su,, Yuan Liu, Xiaomei Wu, Jiangdong Xiang,, and Xiaowei Xi

similar genomic scars resulting in HRD displayed increased sensitivity to chemotherapy. Our study aimed to explore HRD score genetic mechanisms and subsequent clinical outcomes in human cancers especially ovarian cancer. Methods : We analyzed TCGA data of

Full access

Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor

suggested a pelvic serous carcinoma ( Figure 1C , inset). These new CT results and disparate pathologic conclusions suggested the possibility that this patient was incorrectly diagnosed with PDA and instead had advanced serous ovarian cancer. However, before

Full access

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Michael Berry, Saundra S. Buys, Beth Crawford, Meagan Farmer, Susan Friedman, Judy E. Garber, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Huma Rana, Gwen Reiser, Mark E. Robson, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, Rashmi Kumar, and Susan Darlow

often have an early age of onset and exhibit an autosomal dominant inheritance pattern. Advances in molecular genetics have allowed researchers to identify a number of genes associated with inherited susceptibility to breast and/or ovarian cancers (eg

Full access

Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow

assessment of individual breast and ovarian cancer risk and to guide decisions related to genetic testing; and (3) facilitate a multidisciplinary approach in the management of individuals at increased risk for hereditary breast and/or ovarian cancer

Full access

Brandie Heald, Shanna Gustafson, Jessica Mester, Patricia Arscott, Katherine Lynch, Jessica Moline, and Charis Eng

each visit type. Aligned with the greatest reason for referral, hereditary breast-ovarian cancer syndrome (HBOC) from BRCA1 and BRCA2 mutations was the most commonly suspected diagnosis (n=176). GCO visits trended toward seeing significantly more

Full access

Tayyaba Hasan

to PDT in prostate, pancreatic, and ovarian cancer cell models is discussed, featuring the roles of both vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in guiding the selection of targeted agents to join PDT in

Full access

Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer

Overview Specific patterns of hereditary breast and ovarian cancers have been found to be linked to pathogenic or likely pathogenic variants in the BRCA1/2 genes. 1 , 2 In addition, Li-Fraumeni syndrome (LFS), a very rare hereditary cancer